Animal health company Elanco (NYSE:ELAN) reported Q1 CY2025 results beating Wall Street’s revenue expectations, but sales were flat year on year at $1.19 billion. The company’s full-year revenue guidance of $4.55 billion at the midpoint came in 1.1% above analysts’ estimates. Its non-GAAP profit of $0.37 per share was 21.5% above analysts’ consensus estimates.
Once a dominant force in the weight-loss industry, WW International Inc. (NASDAQ: WW), formerly known as WeightWatchers, is feeling pressure from the disruptive rise of anti-obesity drugs, and is now staring at a bankruptcy process to reorganize its finances.
Eli Lilly and Company (NYSE: LLY) shares are trading lower Tuesday. The stock appears to be moving in reaction to an executive order from the Trump administration aimed at boosting domestic drug manufacturing.
President Donald Trump signed an executive order Monday directing the FDA to accelerate approvals for domestic pharmaceutical manufacturing facilities as his administration prepares to announce new tariffs on imported medicines within two weeks
"Too big to fail" is how we would describe the megacap stocks in this article today.
While they will likely stand the test of time, it’s not all sunshine and rainbows as their scale can limit their ability to find new sources of growth.
Viking's leading drug candidate could be a blockbuster in the weight loss market, which experts believe could grow to $150 billion over the coming years.
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY)
fell 11% in the afternoon session after the company reported weak first quarter 2025 results which included an EPS miss due to lower-than-expected profitability and full-year EPS guidance that missed significantly. On the other hand, Eli Lilly narrowly topped analysts' revenue expectations, fueled by surging demand for Mounjaro and Zepbound, which together drove a 45% year-over-year increase in total sales. Still, this was a softer quarter.
